SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Feb 12, 2019
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: Feb. 12, 2019 · CIK: 0001513525 · Accession: 0001213900-19-002196
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229615
Letter
Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911
February 12, 2019
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Todd Schiffman
Re: Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No: 333-229615
Ladies and Gentlemen:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement on Form S-1 (File No. 333-229615), be accelerated by the U.S. Securities and Exchange Commission to Thursday, February 14, 2019, at 9:00 a.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant hereby authorizes its legal counsel, Leslie Marlow, Esq. and/or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact either Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911
February 12, 2019
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Todd Schiffman
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No: 333-229615
Ladies and Gentlemen:
Adial Pharmaceuticals,
Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement
on Form S-1 (File No. 333-229615), be accelerated by the U.S. Securities and Exchange Commission to Thursday, February
14, 2019, at 9:00 a.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant
hereby authorizes its legal counsel, Leslie Marlow, Esq. and/or Patrick J. Egan, Esq. of Gracin & Marlow, LLP, to orally modify
or withdraw this request for acceleration. Please contact either Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at
(914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for
acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
By:
/s/ William B. Stilley
III
Name:
Title:
William
B. Stilley III
Chief Executive Officer
cc:
Leslie Marlow, Esq., Gracin & Marlow,
LLP